These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 19817526

  • 1. Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective.
    Ara R, Rafia R, Ward SE, Wierzbicki AS, Reynolds TM, Rees A, Pandor A.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):423-33. PubMed ID: 19817526
    [Abstract] [Full Text] [Related]

  • 2. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
    Ara R, Pandor A, Stevens J, Rafia R, Ward SE, Rees A, Durrington PN, Reynolds TM, Wierzbicki AS, Stevenson M.
    Eur J Prev Cardiol; 2012 Jun; 19(3):474-83. PubMed ID: 21460076
    [Abstract] [Full Text] [Related]

  • 3. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.
    Ara R, Pandor A, Stevens J, Rees A, Rafia R.
    Health Technol Assess; 2009 Jul; 13(34):1-74, 75-118. PubMed ID: 19604457
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Jul; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jönsson B, IDEAL Trial Investigators.
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [Abstract] [Full Text] [Related]

  • 6. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
    Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Wilkinson A, Durrington P, Chilcott J.
    Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
    [Abstract] [Full Text] [Related]

  • 7. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG).
    Javed U, Deedwania PC, Bhatt DL, Cannon CP, Dai D, Hernandez AF, Peterson ED, Fonarow GC.
    Am Heart J; 2010 Dec; 160(6):1130-6, 1136.e1-3. PubMed ID: 21146668
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
    Barrios V, Lobos JM, Serrano A, Brosa M, Capel M, Alvarez Sanz C.
    J Med Econ; 2012 Dec; 15 Suppl 1():45-54. PubMed ID: 22954062
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.
    Can J Clin Pharmacol; 2009 Dec; 16(2):e331-45. PubMed ID: 19531812
    [Abstract] [Full Text] [Related]

  • 10. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S.
    Circulation; 2007 May 08; 115(18):2398-409. PubMed ID: 17452609
    [Abstract] [Full Text] [Related]

  • 11. Economic implications of lipid-lowering trials: current considerations in selecting a statin.
    Farmer JA.
    Am J Cardiol; 1998 Sep 24; 82(6A):26M-31M. PubMed ID: 9766345
    [Abstract] [Full Text] [Related]

  • 12. How to lose a billion pounds.
    Moon JC, Bogle RG.
    Int J Clin Pract; 2007 Jan 24; 61(1):2-3. PubMed ID: 17229170
    [No Abstract] [Full Text] [Related]

  • 13. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D, Park HJ, Ko SK.
    Clin Ther; 2009 Oct 24; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [Abstract] [Full Text] [Related]

  • 14. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS.
    Palmer SJ, Brady AJ, Ratcliffe AE.
    Int J Clin Pract; 2003 Nov 24; 57(9):792-800. PubMed ID: 14686571
    [Abstract] [Full Text] [Related]

  • 15. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB, Frial T, Miller PS.
    Can J Clin Pharmacol; 2007 Nov 24; 14(2):e205-14. PubMed ID: 17556788
    [Abstract] [Full Text] [Related]

  • 16. A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention.
    Scuffham PA, Chaplin S.
    Clin Ther; 2005 Sep 24; 27(9):1467-77. PubMed ID: 16291420
    [Abstract] [Full Text] [Related]

  • 17. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E.
    J Am Coll Cardiol; 2009 Dec 15; 54(25):2358-62. PubMed ID: 20082923
    [Abstract] [Full Text] [Related]

  • 18. The value of atorvastatin over the product life cycle in the United States.
    Grabner M, Johnson W, Abdulhalim AM, Kuznik A, Mullins CD.
    Clin Ther; 2011 Oct 15; 33(10):1433-43. PubMed ID: 21955936
    [Abstract] [Full Text] [Related]

  • 19. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
    de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, Investigators.
    JAMA; 2004 Sep 15; 292(11):1307-16. PubMed ID: 15337732
    [Abstract] [Full Text] [Related]

  • 20. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY, Ko SK, Liew D.
    Clin Ther; 2009 Dec 15; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.